Remove Containment Remove Drugs Remove FDA Approval Remove Packaging
article thumbnail

Ortho-Phthalates Retain FDA Approval for Food Packaging Despite Petitions

XTalks

Last week, the US Food and Drug Administration (FDA) stood by its decision, denying a petition asking it to reevaluate the use of eight ortho-phthalates in food-contacting packaging materials. Related: Is Fiber Based Packaging the Next Trend in Sustainable Food Packaging?

article thumbnail

What is the Difference Between Biologics and Biosimilars?

Pharma Packaging Solutions

Biologics are drug products that are manufactured using materials from living sources. A biosimilar is a biologic that is similar enough to an existing FDA-approved product that it performs in exactly the same way, but different enough to avoid legal battles with the producers of the original product. Let’s talk about it.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Top 15 Diabetes Drugs in 2023 by 2022 Sales Statistics

XTalks

The top 15 diabetes drugs in 2023, according to 2022 sales data, reflect the current state of diabetes management and hint at the evolving needs and trends within this critical area of healthcare. Read on to learn more about the top 15 diabetes drugs in 2023, based on 2022 sales statistics. mL subcutaneous solution (2 mg/1.5

Sales 52
article thumbnail

Pink Sauce: Everything You Need to Know About TikTok’s Controversial Condiment

XTalks

Yet over the past few weeks, she’s faced numerous questions about Pink Sauce’s ingredients, packaging and marketing, prompting a social media-based food scandal. He showed the bottle label that seemed to indicate that it contains 444 servings of the product, at 60 calories per serving of about a tablespoon — a near mathematical impossibility.

article thumbnail

In the News: September 2021 Regulatory and Development Updates

Camargo

The Center for Drug Evaluation and Research (CDER) has announced the rollout of the Novel Excipient Review Pilot Program in Federal Register Vol. The pilot program is the first step in allowing manufacturers to receive a preliminary review of a novel excipient, prior to drug product formulation.

article thumbnail

In the News: October 2021 Regulatory and Development Updates

Camargo

FDA Guidance Addresses Real-World Evidence Data Standards. The 21 st Century Cures Act generated a good deal of excitement and interest when it added a section called “ Utilizing Real World Evidence ” to the Food, Drug, and Cosmetic Act (Section 505F). FDA Publishes ICH Guidelines on Continuous Manufacturing.

article thumbnail

In the News: November Regulatory and Development Updates

Camargo

If you are facing an FDA remote review, Camargo can help design a comprehensive approach in order to avoid such pitfalls. Approval of the Month: Alnylam to Use Value-Based Agreements for Ultra-rare Disease Treatment. Evergreening Orphan Drugs May Be Over. Without that showing, the FDA is directed to revoke the exclusivity.